Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Pesticide exposure is linked to Parkinson's disease

Individuals whose occupation involves contact with pesticides appear to have an increased risk of having Parkinson's disease, according to a report in the September issue of Archives of Neurology, one of the JAMA/Archives journals.

15 Sep 2009

Vivakor completes third-party validation testing of its VivaBlend nutraceutical product

Vivakor™, Inc. (OTCBB: VIVK) today announced the results of independent, third-party validation testing of its VivaBlend™ nutraceutical product. VivaBlend is a powerful extract developed by the scientists at Vivakor and is derived from over 18 highly bioactive fruits, vegetables and legumes. Through a proprietary formulation and extraction process, Vivakor scientists have maximized the health benefits of VivaBlend by creating an optimum blend of super-antioxidants and powerful plant phenolics and flavonoids.

14 Sep 2009

APDA/NPF Parkinson's conference educates the young onset PD community

The American Parkinson Disease Association (APDA) National Young Onset Center and the National Parkinson Foundation (NPF) Young Onset Parkinson Network are co-sponsoring a series of conferences for those living with young-onset Parkinson's disease and their caregivers. The first conference will be held in Dallas, Texas on October 23-24.

14 Sep 2009

Parkinson Society Canada's SuperWalk raises record amount

SuperWalk for Parkinson's raised a record $2.46 million this year. Lauren Collins, star of Degrassi: The Next Generation, unveiled the new look SuperWalk for 2010 at this year's Toronto walk. Collins, left, walked with her mother, Sari, for her father who has had Parkinson's for over 20 years.

14 Sep 2009

Scientific program to treat and prevent mental disorders

Mental disorders are a global problem and represent one of the biggest challenges for health care systems. In the world, there are some 500 million people suffering from mental disorders, and in the European Union, mental disorders range as one of the leading causes of disease burden.

14 Sep 2009

FDA accepts Merz Pharmaceuticals' premarket approval application for Belotero Balance

Merz Pharmaceuticals, LLC, a leading specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Merz's premarket approval (PMA) application for Belotero(R) Balance.

11 Sep 2009

CytRx granted patent for molecular chaperone amplifier drug candidate

CytRx Corporation, a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that it has been granted a key patent by the European Patent Office that covers through 2024 the use of its orally available molecular chaperone amplifier drug candidate arimoclomol for the treatment or prevention of neurodegenerative diseases of the central nervous system (CNS).

10 Sep 2009

All Americans should have access to affordable and high quality health care: President of BIO

“BIO shares President Obama's goal of ensuring that all Americans have access to affordable, sustainable, high quality health care. Biotechnology plays an essential role in achieving this goal. Biotechnology expands the boundaries of science by discovering, developing, and delivering innovative and needed medical products to patients.

10 Sep 2009

American Asthma Foundation awards $750,000 for asthma research

Dr. Serpil Erzurum, one of the nation's leading experts in asthma, has been awarded $750,000 by the American Asthma Foundation (AAF). Dr. Erzurum will collaborate with experts in nuclear medicine and physics to develop an innovative way for clinicians to observe changes in the lungs of patients during an asthma attack.

9 Sep 2009

St. Jude Medical's Brio neurostimulator receives CE Mark approval

St. Jude Medical, Inc. (NYSE:STJ) today announced CE (Conformité Européenne) Mark approval of the Brio™ neurostimulator, the world’s smallest, longest-lasting rechargeable deep brain stimulation (DBS) device for treating the symptoms of Parkinson’s disease. A 67-year-old man who has suffered from Parkinson’s disease for more than 26 years became the first person to be implanted with the Brio neurostimulator.

9 Sep 2009

Applications invited from scientists for LBD Biomarker Research Award

The Alzheimer's Drug Discovery Foundation (ADDF) and the Lewy Body Dementia Association (LBDA) invite scientists from the biotechnology industry and academia worldwide to apply for a new collaborative research grant award entitled Lewy Body Dementia Biomarker Research Award.

8 Sep 2009

Zinc finger nucleases utilized for modifying hESCs and hiPSCs

Scientists from The Whitehead Institute used zinc finger nucleases (ZFNs) designed by Sangamo BioSciences, Inc., (Nasdaq: SGMO) to efficiently and precisely modify the genomes of human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs).

8 Sep 2009

Prevalence of cortical gray matter atrophy may be overestimated in healthy aging brain

The belief that healthy older brains are substantially smaller than younger brains may stem from studies that did not screen out people whose undetected, slowly developing brain disease was killing off cells in key areas, according to new research. As a result, previous findings may have overestimated atrophy and underestimated normal size for the older brain.

8 Sep 2009

CELDA used for assessing the cerebrospinal fluid granted CE marking

LinkMed’s portfolio company Likvor has been granted CE marking for its instrument for better and safer identification and diagnosis of Normal Pressure Hydrocephalus (NPH).

4 Sep 2009

Brown University neuroscience professor awarded EUREKA grant

Brown University neuroscience professor Gilad Barnea will receive a nearly $1.3 million, four-year federal grant toward development of a method to selectively monitor the activation of each of the five receptors for the neurotransmitter dopamine in the brain.

4 Sep 2009

CRT-D implants for treating sudden cardiac death

Electrophysiologists Robert Stevenson, MD, and Jeffrey L. Williams, MD, MS, FACC, are safely implanting cardiac resynchronization therapy defibrillators in the Good Samaritan Hospital (GSH) Cardiology (Heart Failure) Program.

3 Sep 2009

Clinical research paper on 2D gel electrophoresis for identifying protein biomarkers

Transgenomic, Inc. and Power3 Medical Products, Inc. (OTC Bulletin Board: PWRM) today announced the advance on-line publication of a clinical research paper entitled "Abnormal Serum Concentrations of Proteins in Parkinson's Disease" in the scientific journal Biochemical and Biophysical Research Communications.

3 Sep 2009

Future Alzheimer's treatments may be effective before the onset of symptoms

Memory lapses that occur with normal aging are a source of worry for many who fear Alzheimer's disease. Now a new Mayo Clinic-led study published in the July 16 issue of the New England Journal of Medicine suggests that the carriers of a common genetic risk factor for Alzheimer's disease begin to have memory declines in their mid-50s, far earlier than previously thought.

2 Sep 2009

LINGO1 variant responsible for essential tremors and Parkinson's disease

Researchers at the Mayo Clinic campus in Florida and their collaborators worldwide have discovered that a single gene promotes development of essential tremor in some patients and Parkinson's disease in others.

2 Sep 2009

White matter hyperintensities could lead to permanent thinking problems

Elderly people with no memory or thinking problems are more likely to later develop thinking problems if they have a growing amount of "brain rust," or small areas of brain damage, according to a study published in the July 14, 2009, print issue of NeurologyÂ®, the medical journal of the American Academy of Neurology.

2 Sep 2009